Bhatia Sangeeta N.'s Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Oct 11, 2023
- Accession no.
- 0001209191-23-052622
- Filed
- Oct 11, 2023
- Trade date
- Oct 6, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $87.1K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bhatia Sangeeta N.CIK 0001643921 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 6, 2023 | Common Stock | SSaleDisposed | −242 | $360.00 | −$87,120 | 4,144 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.